AstraZeneca and cycle signed a $1 billion R & D bill to target dicyclic peptide drugs

Source: Medical magic cube data: on December 1, 2016, AstraZeneca signed a cooperation agreement with cycle therapeutics in the United Kingdom with a total amount of US $1 billion, using the latter's proprietary technology platform to develop bicyclic peptide drugs for the treatment of respiratory, cardiovascular and metabolic diseases According to the agreement, cycle will provide dicyclic peptide drug screening services for several targets designated by AstraZeneca, and AstraZeneca will be responsible for the later development and commercial promotion Cycle can obtain undisclosed advance payment, R & D funds and various development, registration and business mileage funds from AstraZeneca, totaling US $1 billion In the future, it can also obtain sales share of related products Bicyclic therapeutics said: "bicyclic peptide is a new type of small molecule drug, which can overcome many limitations of existing drugs It not only has a strong targeting affinity similar to macromolecular monoclonal antibody drugs, but also has a flexible route of drug delivery and rapid tissue permeability similar to small molecule drugs Menelas Pangalos, executive vice president of global BD business of AstraZeneca, said: "the cycle technology platform has improved our new drug discovery ability, and can support us to explore new drug projects on more targets and wider indications." Kevin Lee, CEO of cycle, said: "it's a great pleasure to cooperate with AstraZeneca on the cycle technology platform in multiple disease areas, which also reflects the strong strength of our technology platform We look forward to working with AstraZeneca to develop new therapeutic drugs for unmet medical needs " Kevin was chief scientific officer of rare diseases and genetic diseases at Pfizer before joining the company In 2014, cycle completed round B financing of US $32 million, with investors including atlas venture, Novartis venture fund, Sr one, SV life sciences and Atlas venture management.